132 related articles for article (PubMed ID: 35983098)
1. Predict ovarian cancer by pairing serum miRNAs: Construct of single sample classifiers.
Hong G; Luo F; Chen Z; Ma L; Lin G; Wu T; Li N; Cai H; Hu T; Zhong H; Guo Y; Li H
Front Med (Lausanne); 2022; 9():923275. PubMed ID: 35983098
[TBL] [Abstract][Full Text] [Related]
2. Construct of qualitative diagnostic biomarkers specific for glioma by pairing serum microRNAs.
Li H; Ma L; Luo F; Liu W; Li N; Hu T; Zhong H; Guo Y; Hong G
BMC Genomics; 2023 Mar; 24(1):96. PubMed ID: 36864382
[TBL] [Abstract][Full Text] [Related]
3. Integrated analysis of diverse cancer types reveals a breast cancer-specific serum miRNA biomarker through relative expression orderings analysis.
Ma L; Gao Y; Huo Y; Tian T; Hong G; Li H
Breast Cancer Res Treat; 2024 Apr; 204(3):475-484. PubMed ID: 38191685
[TBL] [Abstract][Full Text] [Related]
4. The serine protease prostasin (PRSS8) is a potential biomarker for early detection of ovarian cancer.
Tamir A; Gangadharan A; Balwani S; Tanaka T; Patel U; Hassan A; Benke S; Agas A; D'Agostino J; Shin D; Yoon S; Goy A; Pecora A; Suh KS
J Ovarian Res; 2016 Mar; 9():20. PubMed ID: 27036110
[TBL] [Abstract][Full Text] [Related]
5. Low-mass-ion discriminant equation (LOME) for ovarian cancer screening.
Lee JH; Yoo BC; Kim YH; Ahn SA; Yeo SG; Cho JY; Kim KH; Kim SC
BioData Min; 2016; 9():32. PubMed ID: 27752286
[TBL] [Abstract][Full Text] [Related]
6. Multi-analytical test based on serum miRNAs and proteins quantification for ovarian cancer early detection.
Cirillo PDR; Margiotti K; Fabiani M; Barros-Filho MC; Sparacino D; Cima A; Longo SA; Cupellaro M; Mesoraca A; Giorlandino C
PLoS One; 2021; 16(8):e0255804. PubMed ID: 34352040
[TBL] [Abstract][Full Text] [Related]
7. A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study.
Lin XJ; Chong Y; Guo ZW; Xie C; Yang XJ; Zhang Q; Li SP; Xiong Y; Yuan Y; Min J; Jia WH; Jie Y; Chen MS; Chen MX; Fang JH; Zeng C; Zhang Y; Guo RP; Wu Y; Lin G; Zheng L; Zhuang SM
Lancet Oncol; 2015 Jul; 16(7):804-15. PubMed ID: 26088272
[TBL] [Abstract][Full Text] [Related]
8. Differential levels of L-homocysteic acid and lysophosphatidylcholine (16:0) in sera of patients with ovarian cancer.
Kim SC; Kim MK; Kim YH; Ahn SA; Kim KH; Kim K; Kim WK; Lee JH; Cho JY; Yoo BC
Oncol Lett; 2014 Aug; 8(2):566-574. PubMed ID: 25013471
[TBL] [Abstract][Full Text] [Related]
9. Predict Colon Cancer by Pairing Plasma miRNAs: Establishment of a Normalizer-Free, Cross-Platform Model.
Qin D; Guo Q; Wei R; Liu S; Zhu S; Zhang S; Min L
Front Oncol; 2021; 11():561763. PubMed ID: 33968711
[TBL] [Abstract][Full Text] [Related]
10. Identification of differential DNA methylation alterations of ovarian cancer in peripheral whole blood based on within-sample relative methylation orderings.
Li H; Jiang F; Du Y; Li N; Chen Z; Cai H; Guo Y; Hong G
Epigenetics; 2022 Mar; 17(3):314-326. PubMed ID: 33749504
[TBL] [Abstract][Full Text] [Related]
11. A risk score system based on a six-microRNA signature predicts the overall survival of patients with ovarian cancer.
Zhou M; Wu T; Yuan Y; Dong SJ; Zhang ZM; Wang Y; Wang J
J Ovarian Res; 2022 May; 15(1):54. PubMed ID: 35513874
[TBL] [Abstract][Full Text] [Related]
12. Identifying primary site of lung-limited Cancer of unknown primary based on relative gene expression orderings.
Li M; Li H; Hong G; Tang Z; Liu G; Lin X; Lin M; Qi L; Guo Z
BMC Cancer; 2019 Jan; 19(1):67. PubMed ID: 30642283
[TBL] [Abstract][Full Text] [Related]
13. A Novel Classifier Based on Urinary Proteomics for Distinguishing Between Benign and Malignant Ovarian Tumors.
Ni M; Zhou J; Zhu Z; Yuan J; Gong W; Zhu J; Zheng Z; Zhao H
Front Cell Dev Biol; 2021; 9():712196. PubMed ID: 34527671
[TBL] [Abstract][Full Text] [Related]
14. Exploration of Potential miRNA Biomarkers and Prediction for Ovarian Cancer Using Artificial Intelligence.
Hamidi F; Gilani N; Belaghi RA; Sarbakhsh P; Edgünlü T; Santaguida P
Front Genet; 2021; 12():724785. PubMed ID: 34899827
[TBL] [Abstract][Full Text] [Related]
15. Profiling of Serum Metabolites Using MALDI-TOF and Triple-TOF Mass Spectrometry to Develop a Screen for Ovarian Cancer.
Lee JH; Kim YH; Kim KH; Cho JY; Woo SM; Yoo BC; Kim SC
Cancer Res Treat; 2018 Jul; 50(3):883-893. PubMed ID: 28934848
[TBL] [Abstract][Full Text] [Related]
16. Prostate cancer early diagnosis: circulating microRNA pairs potentially beyond single microRNAs upon 1231 serum samples.
Liu HP; Lai HM; Guo Z
Brief Bioinform; 2021 May; 22(3):. PubMed ID: 32607548
[TBL] [Abstract][Full Text] [Related]
17. Identification of a three-miRNA panel in serum for bladder cancer diagnosis by a diagnostic test.
Li R; Xia Y; Chen X; Li X; Huang G; Peng X; Liu K; Zhang C; Li M; Lin Y; Dong J; Ji L; Lai Y
Transl Cancer Res; 2022 May; 11(5):1005-1016. PubMed ID: 35706801
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-1-3p inhibits the growth and metastasis of ovarian cancer cells by targeting DYNLT3.
Zhu FJ; Li JZ; Wang LL
Eur Rev Med Pharmacol Sci; 2020 Sep; 24(17):8713-8721. PubMed ID: 32964959
[TBL] [Abstract][Full Text] [Related]
19. Identification of Serum Circulating MicroRNAs as Novel Diagnostic Biomarkers of Gastric Cancer.
Yao Y; Ding Y; Bai Y; Zhou Q; Lee H; Li X; Teng L
Front Genet; 2020; 11():591515. PubMed ID: 33597967
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Diagnostic Potential of Epigenetically Deregulated MiRNAs in Epithelial Ovarian Cancer.
Kumar V; Gupta S; Chaurasia A; Sachan M
Front Oncol; 2021; 11():681872. PubMed ID: 34692473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
